Adage Capital Partners Gp, L.L.C. Coherus Bio Sciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$17.41 - $19.89 $2.18 Million - $2.49 Million	-125,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $360,750 - $479,000	-25,000 Reduced 16.67%	125,000 $2.23 Million
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $875,250 - $1.69 Million	-75,000 Reduced 33.33%	150,000 $2.43 Million
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $4.49 Million - $5.88 Million	-275,000 Reduced 55.0%	225,000 $4.05 Million
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $8.15 Million - $11.7 Million	-500,000 Reduced 50.0%	500,000 $10.1 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $3.28 Million - $5.53 Million	-250,000 Reduced 20.0%	1,000,000 $22.1 Million
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $4.61 Million - $8.53 Million	550,000 Added 78.57%	1,250,000 $17.1 Million
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $6.06 Million - $11.4 Million	700,000 New	700,000 $6.34 Million

143

82.7M

79.1K

100K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $80.8M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.